These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31733591)

  • 1. Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer.
    Tøndell A; Wahl SGF; Sponaas AM; Sørhaug S; Børset M; Haug M
    Transl Oncol; 2020 Jan; 13(1):17-24. PubMed ID: 31733591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral CD39
    Yeong J; Suteja L; Simoni Y; Lau KW; Tan AC; Li HH; Lim S; Loh JH; Wee FYT; Nerurkar SN; Takano A; Tan EH; Lim TKH; Newell EW; Tan DSW
    J Thorac Oncol; 2021 Aug; 16(8):1349-1358. PubMed ID: 33975004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ectonucleotidase CD39 identifies tumor-reactive CD8
    Chow A; Uddin FZ; Liu M; Dobrin A; Nabet BY; Mangarin L; Lavin Y; Rizvi H; Tischfield SE; Quintanal-Villalonga A; Chan JM; Shah N; Allaj V; Manoj P; Mattar M; Meneses M; Landau R; Ward M; Kulick A; Kwong C; Wierzbicki M; Yavner J; Egger J; Chavan SS; Farillas A; Holland A; Sridhar H; Ciampricotti M; Hirschhorn D; Guan X; Richards AL; Heller G; Mansilla-Soto J; Sadelain M; Klebanoff CA; Hellmann MD; Sen T; de Stanchina E; Wolchok JD; Merghoub T; Rudin CM
    Immunity; 2023 Jan; 56(1):93-106.e6. PubMed ID: 36574773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Location of CD39
    Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of the CD8
    Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
    Front Immunol; 2021; 12():687296. PubMed ID: 34177939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].
    Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q
    Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
    Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
    Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDSC subtypes and CD39 expression on CD8
    Koh J; Kim Y; Lee KY; Hur JY; Kim MS; Kim B; Cho HJ; Lee YC; Bae YH; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Eur J Immunol; 2020 Nov; 50(11):1810-1819. PubMed ID: 32510574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
    Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
    Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
    Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
    Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
    PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer CD39 drives metabolic adaption and mal-differentiation of CD4
    Wang Y; Liu M; Zhang L; Liu X; Ji H; Wang Y; Gui J; Yue Y; Wen Z
    Cell Death Dis; 2023 Dec; 14(12):804. PubMed ID: 38062068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoints are predominantly co-expressed by clonally expanded CD4
    Bredel D; Tihic E; Mouraud S; Danlos FX; Susini S; Aglave M; Alfaro A; Mohamed-Djalim C; Rouanne M; Halse H; Bigorgne A; Tselikas L; Dalle S; Hartl DM; Baudin E; Guettier C; Vibert E; Rosmorduc O; Robert C; Ferlicot S; Parier B; Albiges L; de Montpreville VT; Besse B; Mercier O; Even C; Breuskin I; Classe M; Radulescu C; Lebret T; Pautier P; Gouy S; Scoazec JY; Zitvogel L; Marabelle A; Bonvalet M
    J Exp Clin Cancer Res; 2023 Dec; 42(1):333. PubMed ID: 38057799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune profiling identifies CD8
    Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
    Front Immunol; 2022; 13():894919. PubMed ID: 36420264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.